The systemic treatment of recurrent ovarian cancer revisited

T. Baert, A. Ferrero, J. Sehouli, D. M. O'Donnell, A. González-Martín, F. Joly, J. van der Velden, P. Blecharz, D. S.P. Tan, D. Querleu, N. Colombo, A. du Bois, J. A. Ledermann

Research output: Contribution to journalReview articlepeer-review


Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (e.g. pleural effusion, ascites). For patients with recurrent high-grade ovarian cancer, which responds to platinum-based treatment, maintenance therapy with a poly(ADP-ribose) polymerase inhibitor can be offered, regardless of the BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer.

Original languageEnglish
Pages (from-to)710-725
Number of pages16
JournalAnnals of Oncology
Issue number6
Publication statusPublished - Jun 2021


  • platinum re-treatment
  • platinum-based chemotherapy
  • poly(ADP-ribose) polymerase (PARP) inhibitor
  • recurrent ovarian cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The systemic treatment of recurrent ovarian cancer revisited'. Together they form a unique fingerprint.

Cite this